Medicinal Products

Solu-Medrol 250 mg prašak i otapalo za otopinu za injekciju/infuziju

Name Solu-Medrol 250 mg prašak i otapalo za otopinu za injekciju/infuziju
Marketing Authorisation Number HR-H-551195641
Active Substance natrijev metilprednizolonsukcinat
Composition jedna bočica sadrži 250 mg metilprednizolona u obliku natrijevog metilprednizolonsukcinata
Pharmaceutical Form Prašak i otapalo za otopinu za injekciju / infuziju
Manufacturer Pfizer Manufacturing Belgium NV, Puurs, Belgija
Marketing Authorisation Holder Pfizer Croatia d.o.o., Slavonska avenija 6, Zagreb, Hrvatska
Marketing Authorisation Date 20.07.2018
MA Period of Validity unlimited
MA Revocation Date 25.04.2024*
Classification Number UP/I-530-09/16-02/465
Registration Number 381-12-01/30-18-06
Prescription na recept
Type of prescription ograničeni recept
Distribution u ljekarni
Advertising to general public zabranjeno
ATC Code H02AB04
Medicinal product marketed in the Croatia Trajni prekid opskrbe
SmPC download
PL download

*Note

Marketing authorisation has been revoked by request of the marketing authorisation holder. In accordance with Article 113 of Medicinal Products Act (Official Gazette No. 76/13), only a medicinal product in respect of which a marketing authorisation has been granted by the Agency for Medicinal Products and Medical Devices or the European Commision, and a medicinal product in respect of which an authorisation for parallel import or parallel distribution has been granted may be placed on the market of the Republic of Croatia. By way of derogation from this provision, a batch of medicinal product may be on the market for no longer than 18 months following the expiry of revocation of the marketing authorisation, unless its shelf life expires first.

Packaging

Direct Healthcare Professional Communication

Name Date Download
Pismo zdravstvenim radnicima o izmjeni formulacije lijeka Solu-Medrol 125 mg prašak i otapalo za otopinu za injekciju/infuziju (metilprednizolon) i Solu-Medrol 250 mg prašak i otapalo za otopinu za injekciju/infuziju (metilprednizolon) u formulaciju bez konzervansa benzilnog alkohola u otapalu te o mogućem riziku od medikacijske pogreške zbog promjene boje čepa aktivatora 13.04.2021 Pfizer Croatia d.o.o.
Back